Cargando…
Expression of hypoxia‐inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors
BACKGROUND: It has been indicated that abnormal glucose metabolism mediated by hypoxia‐inducible factor 1α (HIF‐1α) played an essential role in the development of solid tumor. However, there were rare studies about the role of them in primary central nervous system lymphoma (PCNSL). OBJECTIVE: To in...
Autores principales: | Shen, Na, Wang, Yaming, Sun, Xuefei, Bai, Xueyan, He, Jinglan, Cui, Qu, Qian, Jun, Zhu, Hong, Chen, Yuedan, Xing, Ruixian, Liu, Qing, Wu, Yuchen, Li, Junhong, Lai, Wenyuan, Sun, Shengjun, Ji, Nan, Liu, Yuanbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428508/ https://www.ncbi.nlm.nih.gov/pubmed/32533646 http://dx.doi.org/10.1002/brb3.1718 |
Ejemplares similares
-
Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study
por: Wu, Yuchen, et al.
Publicado: (2021) -
Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population
por: Wu, Yuchen, et al.
Publicado: (2019) -
Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China
por: Sun, Xuefei, et al.
Publicado: (2022) -
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017) -
Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature
por: Wu, Yuchen, et al.
Publicado: (2018)